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The Temprano and START trials provided evidence to support early ART initiation recom-
mendations. We projected long-term clinical and economic outcomes of immediate ART ini-
tiation in Côte d’Ivoire.
Methods
We used a mathematical model to compare three potential ART initiation criteria: 1) CD4
<350/μL (ART<350/μL); 2) CD4 <500/μL (ART<500/μL); and 3) ART at presentation (Imme-
diate ART). Outcomes from the model included life expectancy, 10-year medical resource
use, incremental cost-effectiveness ratios (ICERs) in $/year of life saved (YLS), and 5-year
budget impact. We simulated people with HIV (PWH) in care (mean CD4: 259/μL, SD 198/
μL) and transmitted cases. Key input parameters to the analysis included first-line ART effi-
cacy (80% suppression at 6 months) and ART cost ($90/person-year). We assessed cost-
effectiveness relative to Côte d’Ivoire’s 2017 per capita annual gross domestic product
($1,600).
Results
Immediate ART increased life expectancy by 0.34 years compared to ART<350/μL and 0.17
years compared to ART<500/μL. Immediate ART resulted in 4,500 fewer 10-year
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transmissions per 170,000 PWH compared to ART<350/μL. In cost-effectiveness analysis,
Immediate ART had a 10-year ICER of $680/YLS compared to ART<350/μL, ranging from
cost-saving to an ICER of $1,440/YLS as transmission rates varied. ART<500/μL was “dom-
inated” (an inefficient use of resources), compared with Immediate ART. Immediate ART
increased the 5-year HIV care budget from $801.9M to $812.6M compared to ART<350/μL.
Conclusions
In Côte d’Ivoire, immediate compared to later ART initiation will increase life expectancy,
decrease HIV transmission, and be cost-effective over the long-term, with modest budget
impact. Immediate ART initiation is an appropriate, high-value standard of care in Côte
d’Ivoire and similar settings.
Introduction
Although international guidelines recommend immediate ART initiation for persons with
HIV infection, many patients in sub-Saharan Africa commonly start ART with advanced dis-
ease, when they already face high morbidity and mortality risk [1]. Timing of ART initiation
has been a debate in HIV clinical care and policy, particularly in resource-limited settings [2,
3]. Multiple clinical trials over the past decade prompted the World Health Organization
(WHO) to change the CD4 threshold for ART initiation, from <200 cells/μL in 2006 to<350
cells/μL in 2010 and then to<500 cells/μL in 2013 [4–6]. In 2015, the Temprano (Côte
d’Ivoire) and START (multi-country) trials showed a 44–58% reduction in mortality or serious
HIV-related illnesses in people with HIV who initiated ART immediately at presentation
regardless of CD4 count compared to those who deferred initiation [7, 8]. In response to these
trials, WHO modified its guidelines in 2015 to recommend ART initiation at diagnosis for all
people with HIV [9].
While most resource-limited countries have adopted immediate treatment, not all have
fully implemented this recommendation, generally due to budget constraints and concerns
about long-term affordability for all those with HIV [10]. While the Temprano and START tri-
als showed the short-term clinical benefits of immediate ART initiation in study settings, the
longer-term clinical and economic outcomes of national implementation of immediate ART
initiation in Côte d’Ivoire and similar settings remain unknown. We addressed these questions
by conducting a cost-effectiveness and budget impact assessment of immediate compared to
delayed ART initiation in people with HIV in care and initiating care in Côte d’Ivoire.
Methods
Analytic overview
We used the Cost-Effectiveness of Preventing AIDS Complications (CEPAC)-International
microsimulation model to assess the clinical benefits, cost-effectiveness, and budget impact of
different ART initiation thresholds in a nationally representative cohort of people with HIV-1
in Côte d’Ivoire [11, 12]. We evaluated the following three ART initiation strategies: 1) CD4
count<350/μL or WHO stage 3–4 (ART<350/μL, until 2013 the standard of care in Côte
d’Ivoire); 2) CD4 count<500/μL or WHO stage 3–4 (ART<500/μL, the standard of care in
Côte d’Ivoire until April, 2017) [10]; or 3) ART initiation when patients present to care,
regardless of CD4 count (Immediate ART), the current WHO recommendation and recent
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guideline in Côte d’Ivoire [9, 13]. We simulated these strategies for the population of people
with HIV in care in Côte d’Ivoire.
We projected several outcomes: life expectancy from time of presentation to care; cumula-
tive 10-year HIV transmissions; 5- and 10-year total medical resource use; 10-year cumulative
life-years saved; and 10-year incremental cost-effectiveness ratios (ICERs) in 2017 US dollars
per year of life saved (YLS). To assess budget impact, we projected 5- and 10-year HIV-related
expenditures for Immediate ART compared to ART<500/μL and ART<350/μL for people with
HIV in care and those projected to initiate ART from 2017–2021 in Côte d’Ivoire. Cost-effec-
tiveness and budget impact also accounted for transmitted cases of HIV. When reported for
purposes of economic evaluation, all outcomes were discounted at a rate of 3% per year. In
accordance with convention, budget impact results were reported undiscounted [14]. We
defined a strategy as cost-effective if its ICER was less than $1,600/YLS, the 2017 annual per
capita GDP in Côte d’Ivoire [15].
Cohort description
Population included in the cost-effectiveness analysis. For the cost-effectiveness analy-
sis, we began by modeling the 170,000 persons currently in care in Côte d’Ivoire, as well as all
incident transmitted cases from this cohort (first-generation and later-generation transmis-
sions over 10 years, S1A Fig). Incident cases began unlinked to care, with characteristics of a
newly-infected population, and presented to care through routine HIV screening or clinical
presentation with an opportunistic disease (OD) [16].
Population included in the budget impact analysis. For the budget impact analysis, we
included HIV-related expenditures incurred by all those in care and entering care in the next 5
years in Côte d’Ivoire. To estimate the number expected to enter care each year (the “present
to care” cohort), we began with historical data showing a yearly average of 14,000 people enter-
ing HIV care in Côte d’Ivoire [17]. For the Immediate ART and the ART<500/μL strategies,
we subtracted the number of transmissions prevented compared with the ART<350/μL strat-
egy from 14,000 to estimate the “present to care” cohort size (S1B Fig).
The CEPAC-International model
Disease model. CEPAC-International is a microsimulation model of HIV natural history,
disease progression, and treatment [12, 18]. Simulated patients are followed monthly from
model entry until death and are generated from user-specified distributions of initial age, sex,
initial CD4 count, HIV RNA, treatment adherence, and OD history. People with HIV who
enter the model not in care can link to care through presentation with an OD or a monthly
probability of having an HIV test and presenting to care. ART is initiated according to strat-
egy-specific CD4 count thresholds or based on an OD. Effective ART reduces HIV RNA and
increases CD4 count; CD4 count determines risk of ODs and death [19, 20]. Additional details
of the model are published and online at http://web2.research.partners.org/cepac [18, 21, 22].
Transmission model. We modeled HIV transmission dependent on stage of infection
(acute, chronic, or end-stage disease) and HIV RNA [23]. The model reports monthly, patient-
level HIV RNA; this depends on baseline HIV RNA, stage of infection, and virologic suppres-
sion on ART. Summing cumulative viral load across 12 months and linking this to HIV RNA-
specific transmission rates determines yearly new infections [23]. In this way, we account for
transmissions from the “first generation” cohort, or transmissions from patients that are simu-
lated from model initiation. We also use this method to calculate transmissions from each pre-
vious year’s newly-infected cohort for up to 10 years. Outcomes in each subsequent year
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include the first-generation cohort as well as all newly infected cohorts from previous years
(S1A Fig).
Model input data
Cohort characteristics and natural history. Simulated people with HIV in care in Côte
d’Ivoire had a mean initial CD4 count of 259/μL (SD: 198/μL) (Table 1). Age and sex distribu-
tions were from the PRECO-CI cohort [16], a nationally representative cohort of people with
HIV in care in Côte d’Ivoire, where the majority of people in care have CD4 counts <500/μL
(88%). Initial HIV RNA distribution was from the Temprano trial [7]. The incidence of tuber-
culosis (TB) for people with HIV at CD4 counts >350/μL was also derived from the Temprano
trial, which closely captured TB incidence data at high CD4 counts [7, 19]. Other natural his-
tory characteristics were from published cohort studies of the HIV-infected population in
Côte d’Ivoire [19, 24–26]. Transmitted cases began the simulation with characteristics of a
newly-infected cohort (high CD4 count, no prior OD history) and were diagnosed and linked
to care, with subsequent treatment as described below, at a mean CD4 count of 259 cells/μL
based on current HIV testing and presentation data [16].
ART regimen. Overall six-month virologic suppression was 80% for both 1st- line (tenofovir
and lamivudine plus efavirenz) and 2nd-line ART (zidovudine and lamivudine plus lopinavir/rito-
navir) regimens. This reflects current 1st-line ART and levels of virologic suppression in clinical
settings in Côte d’Ivoire [25]. Probability of later failure after initial suppression was 0.13–9.0%/
month, depending on adherence [12]. After failure on either regimen, patients received an adher-
ence intervention, with a 54% probability of viral resuppression, consistent with current
approaches to management [35]. Guideline-concordant care for Côte d’Ivoire included twice-
yearly CD4 tests, with HIV RNA confirmation of CD4-defined treatment failure [6, 13].
Transmission. Aggregated transmission probabilities by HIV RNA stratum ranged from
0.16/100PY for HIV RNA<500 copies/mL to 9.03/100PY for HIV RNA>100,000 copies/mL
[23]. Transmission was increased during the 6-month period of acute HIV infection (65.47/
100PY) and during end-stage disease off ART with CD4<200/μL (9.03/100PY) [32].
Cost inputs. Cost inputs to the model included all direct HIV-related medical costs. ART
costs were based on Clinton Health Access Initiative prices and included $90/person/year for
first-line ART and $282/person/year for second-line therapy [33, 34]. OD treatment costs ran-
ged from $80-$555 and CD4-stratified care costs from Côte d’Ivoire ranged from $37-$50/
month [36]. We used Côte d’Ivoire-specific GDP deflators and the average 2017 exchange rate
to convert all cost inputs to constant 2017 US dollars (USD) [15]. The analysis was conducted
from a modified societal perspective (not including patient time costs).
Sensitivity analyses
We assessed key input parameters in sensitivity analysis to evaluate the robustness of our find-
ings to plausible variation in these parameters (ranges in Table 1). Combining influential
parameters identified in one-way sensitivity analyses, we simultaneously varied multiple input
parameters to determine their combined impact on the results. In the base-case analysis, we
assumed no effect of changing ART initiation criteria on overall HIV testing rates. We tested
this assumption in sensitivity analysis by increasing the mean CD4 count at diagnosis for new
infections, as might occur if HIV testing rates increased.
Ethics statement
The CEPAC Data Repository was approved by the Massachusetts General Hospital IRB
(2014P002708/MGH). Within the CEPAC Data Repository, all data are collected by outside
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Table 1. Main input parameters for an analysis of the cost-effectiveness of immediate ART for HIV infection in Côte d’Ivoire.
Parameter Base-case value Range evaluated Reference
Cohort characteristics
Sex, female/male, % 68/32 — [16]
Age, mean (SD) years 37 (9) 18–55 [16]
CD4, mean (SD) cells/μl (Total Cohort) 259 (198) 146–388 [16]







< 49 1 —
Monthly probability of morbidity and mortality, off ART, % §
Monthly OD rates (non-TB) 0.01–9.0 — [19, 27]
Monthly TB rates 0.2–0.7 — [7, 27]
Acute mortality from OD 0.0–16.7 — [19, 27]
Acute mortality from TB 6.5–50.0 — [19, 27]
Monthly probability of death from HIV 0.04–5.4 — [27]
ART efficacy, toxicity, and loss to follow-up
First-line ART�
HIV-1 RNA suppression at 6 months, mean % 80 50–90 [25]
Virologic failure after 6 months, per 100 PY 15 7–22 [25]
Adherence <65%�� 93 — [25]
Adherence >95% 1.6 — [25]
Monthly CD4 increase for those suppressed, mean (SD) cell/μl
Between 0 and 2 months 76 (19) [25]
� 3 months 4 (1) — [25]
Toxicity, %
Minor 11 — [28]
Major 5 — [29]
Toxicity-related mortality, % 0.6 — [28, 29]
Loss to follow-up, per 100 PY [30, 31]
Adherence <65% 13 6–17
Adherence >95% 1.9 5–14
Transmission rates (per 100 PY), by disease stage and viral load [23, 32]
Incident infection (6 months post infection)† 65.47 28.06–152.90
Late stage disease (CD4 <200 cells/μL) 9.03 3.87–21.09
>100,000 copies/mL 9.03 3.87–21.09
10,001–100,000 copies/mL 8.12 2.78–23.77
3,001–10,000 copies/mL 4.17 0.84–20.65
501–3,000 copies/mL 2.06 0.57–7.47
0–500 copies/mL 0.16 0.02–1.13
Costs, 2017 USD
ART, annual [33, 34]
1st-line ART 90 45–135
2nd-line ART 282 141–423
Prophylaxis, annual
(Continued)
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entities and shared with investigators after a quality check by a compliance specialist to ensure
that they meet all specifications of the Data Use Agreement and that all identifiers are
removed. The Temprano data set and consent form were included in the CEPAC Data Reposi-
tory at the time of the initial approval of the protocol. The Temprano trial protocol was
approved by the Côte d’Ivoire Minister of Health and Public Hygiene and the Côte d’Ivoire
National Ethics Committee for Life Sciences and Health (/MSHP/CAB/CNESVS/06). The
Temprano dataset as received from the collaborators in Côte d’Ivoire did not contain any Pro-
tected Health Information. The dataset as received contained limited indirect identifiers neces-
sary for the analyses, but it was stored in a restricted secure network drive to which only
named CEPAC investigators and biostatisticians have access. The biostatistical team generated
completely anonymized aggregate inputs to be used in the model, which were then made avail-
able to the larger study team. As the research project was limited to use of existing secondary
data provided by the Temprano investigators in a de-identified format, the Partners Human
Research Committee waived the requirement for informed consent.
Results
Clinical outcomes
Discounted life expectancy from presentation to care increased from 16.05 years with
ART<350/μL to 16.22 with ART at 500/μL and to 16.39 years with Immediate ART (Table 2A).
Cumulative transmissions arising from the 170,000 persons in care and their transmitted cases
over 10 years decreased from 47,500 with ART<350/μL to 43,000 with Immediate ART, a
decrease of 9.8% (Table 2A and Fig 3 bottom). Because most people in care in Côte d’Ivoire
have a CD4 count<350/μL, there were 22,780 people with CD4 counts 350-500/μL and 20,400
people with CD4 counts >500/μL at simulation start; thus the Immediate ART strategy
changed care in 12% of the in-care population. When we included life-years saved from trans-
missions averted over 10 years and compared total life-years to ART<350/μL, ART<500/μL
saved 12,000 years of life and Immediate ART saved an additional 4,000 years of life (both
discounted).
Costs and cost-effectiveness analysis
Over 10 years, total discounted costs increased from $1.057 billion with ART<350/μL to
$1.065 billion for ART<500/μL and to $1.068 billion with Immediate ART. Compared to
Table 1. (Continued)
Parameter Base-case value Range evaluated Reference
Co-trimoxazole 27 — [18]
Laboratory monitoring, per test
CD4 test 13 — CeDReS
HIV RNA test 40 — CeDReS
OD treatment costs (range by OD) 80–555 [18]
ART: antiretroviral therapy; SD: standard deviation; USD: 2017 US dollars; PY: person-years; CeDReS: Centre de diagnostic et de Recherche sur le SIDA et les
Affections Opportunistes at Treichville University Hospital, Abidjan, Côte d’Ivoire; OD: opportunistic disease
§ Morbidity and mortality ranges in patients from higher to lower mean CD4 strata
�1st-line ART: tenofovir + lamivudine + efavirenz
��Based on Medication Possession Ratio [25]
†The transmission rate for incident infection is derived as 7.25�9.03 [23, 32]
https://doi.org/10.1371/journal.pone.0219068.t001
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ART<350/μL, Immediate ART was cost-effective with an ICER of $680/YLS, well below the
annual per capita GDP in Côte d’Ivoire (Table 2, undiscounted results in S1 Table). ART<500/
μL had a higher ICER than Immediate ART (ICER $680/YLS compared to ART<350/μL) and
by convention, we labeled this strategy “dominated,” or an inefficient use of economic
resources.
Sensitivity analyses
One-way sensitivity analyses. In one-way sensitivity analyses, with variation across plau-
sible input ranges, the ICER for Immediate ART compared to ART<350/μL, as well as to
ART<500/μL, remained below the annual Côte d’Ivoire per capita GDP (Fig 1). ART<500/μL
was no longer a “dominated” strategy if costs of 1st- and 2nd-line ART were higher, mean CD4
count at diagnosis for the prevalent cohort was lower, or HIV transmission rates were lower (�
in Fig 1). Compared to ART<350/μL, the cost-effectiveness of Immediate ART was most sensi-
tive to HIV transmission rates stratified by HIV RNA level, first-line ART cost, and first-line
ART efficacy at presentation for incident cases.
When we varied transmission rates across their literature-based 95% CI (3.28–9.70/100PY),
Immediate ART ranged from cost-saving to an ICER of $1,440/YLS; with higher transmission
rates Immediate ART was more cost-effective. When 1st-line ART costs were varied from $45-
135/year (base-case: $90/year), the ICER ranged from $380/YLS to $1,050/YLS. Immediate
ART became more cost-effective (ICER $330/YLS) with higher CD4 count at diagnosis for
incident cases (574 cells/μL), as might be the case with increased testing, and less cost-effective
(ICER $750/YLS) with lower CD4 count at diagnosis (221 cells/μL), if testing were to decrease.
Table 2. Clinical and economic outcomes of ART initiation according to CD4 threshold or immediate ART initiation in Côte d’Ivoire.
Transmissions and cost-effectiveness�






ART<350/μL 16.05 47,500 1,379,000 1,056,630,000 -
ART<500/μL 16.22 44,800 1,391,000 1,064,610,000 Dominated��
Immediate ART 16.39 43,000 1,395,000 1,067,610,000 680
5-year budget impact, 2017 USD, in millions‡







ART<350/μL 85.5 40.2 676.3 801.9 -
ART<500/μL 91.2 41.0 676.7 809.0 7.1 (0.88)
Immediate ART 94.8 41.6 676.2 812.6 10.7 (1.33)
y: year; ICER: incremental cost-effectiveness ratio; ART: antiretroviral therapy; YLS: year of life saved.
�Results in panel A (except for transmission outcomes) are discounted at 3% per year. The results are for the prevalent cohort of 170,000 people with HIV in care in
Côte d’Ivoire and their transmitted cases. Life-years and costs are rounded after calculating the ICER.
†Life expectancy is reported from time at entry to care.
‡Results in panel B are undiscounted by convention [14]. The results are for the prevalent cohort of 170,000 people with HIV in care in Côte d’Ivoire, their transmitted
cases, and the additional estimated number of persons entering HIV care each year.
��Dominated: A strategy that is less cost-effective (higher ICER) than the next most costly option, and thus not an economically efficient use of resources [14]. The ICER
for ART<500/μL compared to ART<350/μL is $680/YLS.
https://doi.org/10.1371/journal.pone.0219068.t002
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Multi-way sensitivity analyses. We simultaneously varied transmission rates, mean CD4
count at diagnosis for incident cases, and first-line ART cost across wide ranges (Fig 2). When
we held each of these at their base-case values, increasing transmission rates 1.9-fold or more
made Immediate ART cost-saving (Fig 2, panel B, O). If the cost of first-line ART was lowered
to $75/year, no combination of input parameter variation resulted in an ICER for Immediate
ART above $1,600, Côte d’Ivoire’s 2017 annual per capita GDP (Fig 2, panel A). Only if ART
costs increased 1.5-fold and transmission rates decreased to less than 0.7-fold did the ICER for
Immediate ART rise above the Côte d’Ivoire annual per capita GDP (Fig 2, Panel C).
Transmissions and budget impact
At 5 years, ART<500/μL and Immediate ART increased the budget compared to ART<350/μL
by 0.88% and 1.33%, from $801.9 million to $809.0 million and $812.6 million (undiscounted).
The annual expenditures over the first 5 years for ART<500/μL compared to ART<350/μL
ranged from $1.0 million to $2.5 million and for Immediate ART compared to ART<350/μL
ranged from $1.4 million to $4.4 million (S4 Table). In the Immediate ART strategy at 5 years,
laboratory monitoring costs increased by 0.2% and ART costs increased by 1.2% compared to
ART<350/μL; other HIV care costs did not change substantially (S2 Fig).
Delayed ART initiation increases both morbidity and mortality, as observed by the greater
number of life-years gained from immediate ART initiation compared with delayed initiation
(ART<500/μL) across initial CD4 counts (S2 Table). As the mean CD4 count at presentation
to care of the incident cohorts increases, newly-infected patients spend more time in care and
Fig 1. One-way sensitivity analysis, Immediate ART strategy compared to ART<350/μL. This tornado diagram depicts the impact of uncertainty in various input
parameter ranges on the incremental cost-effectiveness ratio (ICER) of Immediate ART compared to ART<350/μL, except for asterisked bounds (�), which are
compared to ART<500/μL. The bold black vertical line crosses the horizontal axis at the base-case ICER of $680/YLS. Each bar represents the effect of changing one
input parameter across its plausible range, and plotting the resulting ICERs of Immediate ART compared to ART<350/μL (or to ART<500/ μL in cases where
Immediate ART does not display extended dominance compared to ART<500/ μL; see Methods for details). Along the vertical axis, the parameter varied is reported as
(Base-case value; value leading to lower ICER-value leading to higher ICER). No changes in individual parameters increase the ICER to over the 2017 annual per capita
GDP in Côte d’Ivoire of $1,600 (dashed vertical line). ART: antiretroviral therapy; YLS: years of life saved; GDP: annual per capita gross domestic product. OD:
opportunistic disease.
https://doi.org/10.1371/journal.pone.0219068.g001
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PLOS ONE | https://doi.org/10.1371/journal.pone.0219068 June 27, 2019 8 / 16
waiting to meet treatment criteria with the delayed ART strategies, while at risk of developing
ODs and incurring additional treatment costs. Thus, the total costs of ART<500/μL approach
and then exceed the total costs of Immediate ART as the mean CD4 counts of the incident
cohorts increase, as would likely be seen with increased testing (S2 Table). Over 10 years, the
Immediate ART strategy also had a larger impact on decreasing transmissions than on increas-
ing the budget; these differences became even more pronounced as the CD4 count at diagnosis
increased (Fig 3).
Discussion
We assessed the clinical impact, cost-effectiveness, and budget impact of immediate ART initi-
ation for all people with HIV currently in care in Côte d’Ivoire, regardless of CD4 count, as
well as those presenting to HIV care over the next 5 years. The latest HIV treatment guidelines
Fig 2. Multi-way sensitivity analysis on transmission rate, CD4 count at diagnosis, and ART costs in a model-based analysis of Immediate ART initiation in Côte
d’Ivoire. This shows the impact of uncertainty in three key input parameters on the incremental cost-effectiveness ratio (ICER) of Immediate ART compared to
ART<350/μL. We varied transmission rates across reported 95% confidence intervals on the vertical axis. On the horizontal axis, we varied the CD4 count at which
transmitted cases present to care. Panel A represents a yearly first-line ART cost of $75. Panel B represents base-case ART costs. The base-case combination of input
parameters is marked with the X. The parameter combination at which Immediate ART becomes cost-saving is marked with an O. Panel C represents yearly first-line
ART costs that are 1�5x base-case values ($135). Combinations of the above parameters that resulted in ICERs that are cost-saving are in green,<0�5x the Côte d’Ivoire
annual per capita GDP ($1,600) in yellow, 0�5-1x GDP in orange, and>1x GDP in red. ART: antiretroviral therapy; GDP: annual per capita gross domestic product.
https://doi.org/10.1371/journal.pone.0219068.g002
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in Côte d’Ivoire recommend immediate ART for all people with HIV; this analysis used
nationally representative data to evaluate this guideline change. Our analysis had three main
findings.
First, compared to ART<350/μL, Immediate ART improved overall discounted life expec-
tancy from presentation to care (from 16.05 years to 16.39 years) and reduced HIV transmis-
sions over 10 years (from 47,500 to 43,000). Second, Immediate ART is cost-effective
compared to both ART<350/μL and ART<500/μL. While the increases in life expectancy are
relatively small, particularly when averaged across all persons already in care, the increases in
costs are also small, since most people with HIV in care in Côte d’Ivoire are already on ART,
Fig 3. HIV care budget increase and reduction in transmissions by ART initiation strategy and CD4 count at presentation to
care, both after 10 years. The 10-year change in budget, top, and 10-year change in transmission, bottom, for the ART<500/μL
(blue) and Immediate ART (orange) strategies compared to ART<350/μL, is shown by CD4 count at presentation to care ranging
from 207/μL to 569/μL (base-case 259/μL). ART<500/μL and Immediate ART proportionally reduce transmissions substantially
more than they increase the budget at 10 years. If incident cases present with higher CD4 counts, due to increased testing and
outreach, the reduction in transmission is even greater. ART: antiretroviral therapy.
https://doi.org/10.1371/journal.pone.0219068.g003
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and Immediate ART will prevent additional transmissions, thus avoiding future care costs.
When we examined the 170,000 people with HIV in care in Côte d’Ivoire, and their transmit-
ted cases, the incremental cost-effectiveness ratio for Immediate ART compared to ART<350/
μL was $680/YLS, less than half the per capita GDP in Côte d’Ivoire ($1,600). Third, compared
to ART<350μL, Immediate ART increased the 5-year HIV budget in Côte d’Ivoire by 1.3%, a
modest increase that accounted for current patients, as well as those newly-diagnosed and
likely to enter care during the subsequent five years.
Our cost-effectiveness conclusions were robust to wide variations in key clinical character-
istics and costs. When single parameters were varied, the ICER of Immediate ART never
exceeded the per capita GDP in Côte d’Ivoire. In multiway sensitivity analyses, the ICER of
Immediate ART remained below $1,600/YLS for plausible combinations of transmission rates,
CD4 counts at diagnosis for incident cases, and first-line ART efficacies. Only if ART costs
increased by 1.5-fold did the ICER begin to exceed the Côte d’Ivoire per capita GDP. However,
as ART costs in resource-limited settings have historically decreased over time, this is unlikely.
Further, even new integrase-inhibitor based regimens are now being priced at $75/person/year
in many resource-limited settings [37]; if this occurs in Côte d’Ivoire Immediate ART would
be even more cost-effective. Finally, if we examine a longer time horizon than 10 years, Imme-
diate ART becomes even more cost-effective. At 15 years, the ICER for Immediate ART com-
pared to ART<350/μl decreases to $330/YLS (from $680/YLS at 10 years); at 20 years, the
ICER for Immediate ART further decreases to $250/YLS.
This study adds to the growing literature demonstrating the clinical benefit and cost-effec-
tiveness of earlier ART initiation among HIV-infected individuals [38, 39]. Similar to our find-
ings, they found immediate ART to be cost-effective or cost-saving. Kuznik et al. used a
Markov model to examine immediate ART in South Africa, Nigeria, Uganda, and India, and
found that immediate ART would be either cost-saving or cost-effective using a 1X per capita
GDP threshold [40]. McCreesh et al. similarly found immediate ART to be cost-effective by
similar criteria in a model focused in Uganda [41]. Our analysis also complements the clinical
findings of the Temprano trial. We demonstrate additional projected long-term clinical benefit
and economic value to Immediate ART compared to ART<500/μL.
A major concern regarding immediate ART provision is the budget impact associated with
treating all patients. We found that the 5-year budget impact of Immediate ART as a strategy
compared to ART<350/μL is modest in the context of the overall HIV program in Côte
d’Ivoire (1.3% increase, or $10.7M). This is because many people with CD4 counts >350/μL in
Côte d’Ivoire, and elsewhere, have not yet been tested for HIV and are not in care; additionally,
most of those currently tested do not have CD4 counts >500/μL. If Immediate ART were com-
bined with increased HIV testing efforts, resulting in a higher mean CD4 count at linkage to
care, we found, however, that the absolute budget impact of Immediate ART would be even
less. This is due to savings from preventing opportunistic diseases, such as tuberculosis and
bacterial infections, which are the most common complications in Côte d’Ivoire and similar
settings in people with higher CD4 counts, as well as preventing HIV transmissions. In fact,
recent evidence suggests that increasing ART availability may itself increase the number of
patients seeking HIV testing, even without any testing-specific interventions [42].
This analysis has several limitations. First, simulation models necessarily simplify complex
biological processes and procedures, and not all data are available from a single setting. We
used transmission rates from published meta-analyses, rather than specifically from Côte
d’Ivoire. We found, however, that the cost-effectiveness conclusions were robust to variations
in these rates. Second, we derived clinical care costs from a single setting in Côte d’Ivoire. The
results did not change even when we varied these costs widely. Third, we did not specifically
account for NNRTI resistance in the model. The immediate ART strategy, however, remained
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cost-effective even with lower ART efficacy, as might be found with primary drug resistance.
In the cost-effectiveness analysis, we examined outcomes only for individuals in HIV care and
their transmitted cases. As a result, our transmission projections do not include those occur-
ring from people not in care. There was no material change in the qualitative findings and con-
clusions of the cost-effectiveness analysis when we varied the number of transmissions
included. We also did not adjust for health-related quality of life in this analysis. Since addi-
tional years lived will be in less than perfect health, our costs per year of life saved would be
lower than cost per quality-adjusted life-year (QALY) or disability-adjusted life-year. However,
if immediate ART increases quality of life in addition to improving survival, our costs per year
of life saved would be higher than cost per QALY. It is also not clear that there is a strong rela-
tionship between CD4 count and health-related quality of life in the current era of effective
ART [43, 44]. Thus, readers should interpret our comparison to the WHO-CHOICE GDP
threshold with caution. Finally, we did not specifically include the cost of any increased testing,
which would further increase the number of people in care in Côte d’Ivoire. However, we and
others have shown that HIV testing itself is highly cost-effective in multiple settings, including
those with both higher and lower prevalence than in Côte d’Ivoire [45–48]. In this analysis,
even if increased testing increased the CD4 count at presentation, Immediate ART would
remain cost-effective. As the number of people in care increased, total outlays would also
increase.
The pressing question of ‘when to treat’ HIV-infected individuals in resource-limited set-
tings has been answered in recent clinical trials, with immediate ART treatment demonstrating
clear short-term clinical superiority over delayed treatment strategies [6–8]. In this analysis,
we aimed to assess the longer-term clinical and economic implications of immediate ART ini-
tiation, focusing on Côte d’Ivoire, a nation with high HIV prevalence in West Africa. We
found that ART initiation at presentation would increase life expectancy, decrease HIV trans-
missions, and be highly cost-effective, all with a modest budget impact over 5 years. Immediate
ART is an appropriate standard of care in Côte d’Ivoire and similar countries in sub-Saharan
Africa and should be fully implemented.
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S1 Fig. Populations modeled in the cost-effectiveness and budgetary impact analyses of a
model-based analysis of early ART initiation in Côte d’Ivoire. The populations included in
the cost-effectiveness analysis (Panel A) were the 170,000 persons currently in care in Côte
d’Ivoire (CI) as well as all transmitted cases arising from this population (including first gener-
ation and higher order transmissions). We restricted the population modeled to persons in
care, and their transmitted cases, excluding persons with undiagnosed HIV, to isolate the effect
of a policy change regarding ART initiation criteria. The populations modeled in the budget
impact analysis (Panel B) included the 170,000 persons currently in care in Côte d’Ivoire and
their transmitted cases, as well as persons newly presenting to care each year over the next five
years. Each outlined box represents the entry of the specified cohort into the analysis. To esti-
mate the number expected to enter care each year over the next 5 years (the “present to care”
cohort), we began with historical data showing a yearly average of 14,000 people entering HIV
care in Côte d’Ivoire [17]. For the Immediate ART and the ART<500/μL strategies, we sub-
tracted from the 14,000 the number of transmissions prevented compared with the ART<350/
μL strategy. Because the ART<350/μL cohort has the most transmissions of the strategies mod-
eled, any transmissions averted by ART<500/μL and Immediate ART are excluded in the bud-
get impact analysis for those strategies. We included an estimate of the costs of undiagnosed
persons presenting to care in Côte d’Ivoire in the budget impact analysis to better project total
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S2 Fig. 5-year budget impact of ART at CD4 counts <500/μL and immediate ART initia-
tion compared to ART at CD4 counts <350/μL in Côte d’Ivoire. Each bar represents the
5-year proportional budget impact of ART<500/μL (left) and Immediate ART (right) com-
pared to ART<350/μL. The height of the bars represents the impact on the total budget, mea-
sured in % budget increase compared to ART<350/μL. The change in other HIV care costs
(orange), laboratory monitoring costs (blue), and ART costs (green) are also shown as a pro-
portion of the change in total costs compared to ART<350/μL Most of the budget increases for
ART<500/μL and Immediate ART at 5 years are in ART costs. ART: antiretroviral therapy.
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